Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +0.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,179)

clinicaltrialsPublishedShowing 151–200 of 666 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04929041	Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative	active not recruiting	Phase 2 / Phase 3	427	National Cancer Institute (NCI)NIH	1	Aug 18, 2026	clinicaltrials
NCT06376084	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC(FOREFRONT)	active not recruiting	—	532	AstraZenecaINDUSTRY